254737-29-6

2-MPPA (10, 30 or 100 mg/kg) significantly attenuates Dizocilpine (HY-15084B) (0.1 mg/kg)-induced prepulse inhibition (PPI) deficits in mice, in a dose dependent manner. The efficacy of 2-MPPA on dizocilpine-induced PPI deficits is significantly antagonized by pretreatment with the selective group II metabotropic glutamate receptor (mGluR) antagonist LY341495 (HY-70059) (1.0 mg/kg)^[1].
2-MPPA (30 mg/kg) significantly prevents the deficit in SNCV induced by both 5 and 25 mg/kg taxol by 96.3 ± 4.4% and 98.3± 11.6% respectively^[2].
2-MPPA (10 mg/kg) inhibits tumor growth in the high expressor PSMA model CWR22RS by 70%^[2].